Chronic lymphocytic leukaemia trials in Switzerland
7 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Where
- Bellinzona, Bern
- Age
- 18 years and over
- People
- 490 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00 - No phaseTaking peopleStudy of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
- Where
- Aarau, Bellinzona, Bern, Lucerne, Münsterlingen, Neuchâtel, Sankt Gallen, Thun, Winterthur
- Age
- 18 years and over
- People
- 500 worldwide
- Run by
- AbbVie
See details and how to joinNCT03342144 - Phase 3Taking peopleA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Where
- Bern, Zurich
- Age
- 18 years and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06973187 · EU 2025-522860-34-00 - Phase 1Taking peopleA Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Where
- Basel, Bellinzona, Bern, Geneva, Sankt Gallen, Zurich
- Age
- 18 years and over
- People
- 572 worldwide
- Run by
- Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00 - No phaseTaking peopleTransgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
- Where
- Aarau
- People
- 50 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06357754 - Phase 1Not yet taking people in SwitzerlandBispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)
- Where
- Basel
- Age
- 18 years and over
- People
- 12
- Run by
- University Hospital, Basel, Switzerland
See details and how to joinNCT07166549 - Phase 1/2Taking peopleSafety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- Where
- Sankt Gallen
- Age
- 18 years and over
- People
- 84 worldwide
- Run by
- Kartos Therapeutics, Inc.
See details and how to joinNCT04502394